BioDelivery Sciences International (NASDAQ:BDSI) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of BioDelivery Sciences International (NASDAQ:BDSIGet Rating) in a research note issued to investors on Monday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Several other brokerages have also weighed in on BDSI. Northland Securities lowered BioDelivery Sciences International from an “outperform” rating to a “market perform” rating in a report on Tuesday, February 15th. HC Wainwright upped their target price on BioDelivery Sciences International from $4.00 to $4.50 and gave the company a “neutral” rating in a report on Friday, January 21st. Truist Financial lowered BioDelivery Sciences International from a “buy” rating to a “hold” rating in a report on Friday, February 25th. Piper Sandler lowered BioDelivery Sciences International from an “overweight” rating to a “neutral” rating and increased their price objective for the stock from $5.00 to $5.60 in a report on Tuesday, February 15th. Finally, Cantor Fitzgerald downgraded BioDelivery Sciences International from an “overweight” rating to a “hold” rating and set a $5.60 target price for the company. in a research report on Friday, February 18th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $5.93.

Shares of BioDelivery Sciences International stock opened at $5.59 on Monday. The business’s fifty day moving average price is $5.58 and its 200 day moving average price is $4.15. The stock has a market capitalization of $577.05 million, a P/E ratio of 6.74 and a beta of 0.56. BioDelivery Sciences International has a twelve month low of $2.50 and a twelve month high of $5.62. The company has a current ratio of 2.45, a quick ratio of 2.17 and a debt-to-equity ratio of 0.29.

BioDelivery Sciences International (NASDAQ:BDSIGet Rating) last released its quarterly earnings results on Wednesday, March 9th. The specialty pharmaceutical company reported $0.62 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.02 by $0.60. BioDelivery Sciences International had a return on equity of 21.25% and a net margin of 50.90%. As a group, sell-side analysts predict that BioDelivery Sciences International will post 0.38 EPS for the current year.

In related news, insider James Vollins sold 18,541 shares of the stock in a transaction dated Friday, February 4th. The shares were sold at an average price of $3.60, for a total value of $66,747.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 9.98% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of BDSI. Morgan Stanley boosted its position in shares of BioDelivery Sciences International by 338.7% during the second quarter. Morgan Stanley now owns 103,491 shares of the specialty pharmaceutical company’s stock worth $372,000 after purchasing an additional 79,903 shares in the last quarter. Millennium Management LLC increased its stake in shares of BioDelivery Sciences International by 118.3% during the 2nd quarter. Millennium Management LLC now owns 51,995 shares of the specialty pharmaceutical company’s stock worth $186,000 after purchasing an additional 28,177 shares during the last quarter. Invesco Ltd. increased its stake in shares of BioDelivery Sciences International by 57.2% during the 2nd quarter. Invesco Ltd. now owns 37,301 shares of the specialty pharmaceutical company’s stock worth $134,000 after purchasing an additional 13,572 shares during the last quarter. Janney Montgomery Scott LLC increased its stake in shares of BioDelivery Sciences International by 223.8% during the 3rd quarter. Janney Montgomery Scott LLC now owns 137,595 shares of the specialty pharmaceutical company’s stock worth $497,000 after purchasing an additional 95,095 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in BioDelivery Sciences International in the 3rd quarter valued at about $226,000. 64.40% of the stock is owned by institutional investors.

About BioDelivery Sciences International (Get Rating)

BioDelivery Sciences International, Inc, a specialty pharmaceutical company, engages in the development and commercialization of pharmaceutical products for chronic conditions in the United States and internationally. The company provides its products based on its patented BioErodible MucoAdhesive drug-delivery technology, a small erodible polymer film for application to the buccal mucosa, as well as other drug delivery technologies.

Featured Articles

Analyst Recommendations for BioDelivery Sciences International (NASDAQ:BDSI)

Receive News & Ratings for BioDelivery Sciences International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioDelivery Sciences International and related companies with MarketBeat.com's FREE daily email newsletter.